Product Description
C&C Research Labs, a subsidiary of JW Pharmaceutical, and XtalPi, a U.S.-based artificial intelligence drug development company, said they will cooperate in developing small molecule therapeutics, focusing on targeting the STAT6 protein, a key player in inflammatory immune responses. (Sourced from: https://www.koreabiomed.com/news/articleView.html?idxno=22807)
Mechanisms of Action: STAT6 Degrader
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: JW Pharma
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 0: Dermatitis, Atopic
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|